CMS finalized the Medicare Drug Price Negotiation Program rule (CMS-4215-F), carving out policy details that matter most for smaller biopharma. The final rule includes determinations for fixed-dose combination or new formulations that CMS treats as “new formulations of existing drugs,” and it implements the Temporary Floor for Small Biotech Drugs for initial price applicability years 2029 and 2030. The coverage emphasizes that CMS finalized an approach to aggregate certain fixed combinations and alternative routes of administration into eligibility for a single qualifying single source drug and maximum fair price, rather than requiring separate eligibility by formulation. Industry groups—including BIO and PhRMA—argued CMS should defer to FDA’s application-based framework to avoid “product hopping” concerns. From an execution standpoint, the final rule shifts how developers may structure lifecycle changes around route conversions or formulation updates. It also sets negotiating eligibility expectations ahead of the program’s next applicability window, affecting pipeline and corporate strategy for mid-to-small sponsors.